---
title: TARGET-NASH Observational Study Reaches 5,000 Enrolled Patients
description: >-
  Read the latest news on regulatory-grade real-world evidence: TARGET-NASH
  Observational Study Reaches 5,000 Enrolled Patients.
date: '2020-04-14'
category: News
tags:
  - Registry / Cohort Milestone
  - R&D
  - Hepatology
  - MASH/MASLD
canonical_url: >-
  https://www.pedestalhealth.com/resources/news/registry-cohort-milestone/target-nash-observational-study-reaches-5-000-enrolled-patients/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: target-nash-observational-study-reaches-5-000-enrolled-patients
id: 7GpSP6cFZJl1oUrzd5V10b
contentType: article
---

***Now Largest Real-World Evidence Nonalcoholic Fatty Liver Disease Study in the World***

TARGET PharmaSolutions, a real-world clinical data company, today announced that its nonalcoholic fatty liver disease (NAFLD) study, TARGET-NASH, reached 5,000 enrolled patients. TARGET-NASH is now the largest active observational and longitudinal NASH-specific study in the world.

“TARGET-NASH has reached 5,000 enrolled patients in only its fourth year of data collection,” said TARGET PharmaSolutions CEO, Neal Bibeau. “This regulatory-grade data is providing tremendous insight about the burden of the disease and is accelerating our partners’ understanding of these patients and the most effective strategies to bring innovative solutions to treat the disease.”

TARGET-NASH is an observational study of participants diagnosed with nonalcoholic fatty liver (NAFL) and/or NASH.  The network of TARGET clinical sites includes both community and academic centers and enrolls adult and pediatric participants across the spectrum of the disease. Once enrolled, three years of retrospective data and five years of prospective data is collected from study participants, including patient-reported outcome measures and biorepository samples.

TARGET-NASH was the first disease community established by TARGET when the company launched in 2015. Since then, TARGET has developed six additional communities including hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC), immune-mediated inflammatory skin conditions (DERM), chronic hepatitis B (HBV), and most recently, TARGET-ASTHMA.

To create each real-world community, the TARGET model organizes groups of stakeholders around specific diseases to produce regulatory-grade data and analysis on the disease’s natural history, current treatment paradigms, and patient outcomes. Stakeholders includes key scientific leaders, regulatory agencies, pharmaceutical manufacturers, and patient advocacy groups who are involved in answering critical strategic and planning questions.